Clinical Trials | March 03, 2026
Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial
Merck emphasized the broader significance of the findings
Merck emphasized the broader significance of the findings
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The innovative eyedrop targets inflammation and pain following ocular surgery
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
Subscribe To Our Newsletter & Stay Updated
